Nautilus Biotechnolgy (NAUT)
NASDAQ:NAUT
Top Page
Nautilus Biotechnolgy
(NASDAQ:NAUT)
Select Model
Select Model
Rating:52Neutral
Price Target:
$3.00
▼(-4.15% Downside)
Action:ReiteratedDate:03/25/26
The score is held back primarily by weak financial performance (pre-revenue, ongoing losses and cash burn) and limited valuation support (negative P/E, no dividend). Technicals are currently strong but overbought, while the earnings call adds moderate support through improved cash discipline and tangible technical progress despite a slow, execution-dependent revenue ramp and higher 2026 burn guidance.
Positive Factors
Proprietary Voyager platform and external validation
The Voyager instrument’s public debut and favorable researcher feedback represent tangible platform validation, strengthening Nautilus’s competitive moat in high-throughput proteomics. Durable technical credibility aids long-term adoption by research and pharma partners, underpinning future instrument and consumables revenue.
Negative Factors
Zero reported revenue and persistent net losses
Nautilus has no reported product revenue and continues to record sizable net losses, indicating the business is still pre-commercial. Absent a demonstrable, scalable revenue stream, the company must rely on financing to fund operations, creating ongoing execution and dilution risk over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary Voyager platform and external validation
The Voyager instrument’s public debut and favorable researcher feedback represent tangible platform validation, strengthening Nautilus’s competitive moat in high-throughput proteomics. Durable technical credibility aids long-term adoption by research and pharma partners, underpinning future instrument and consumables revenue.
Read all positive factors
Nautilus Biotechnolgy (NAUT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$396.15M
Dividend YieldN/A
Average Volume (3M)394.63K
Price to Earnings (P/E)―
Beta (1Y)1.35
Revenue GrowthN/A
EPS Growth11.15%
CountryUS
Employees134
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.11
Shares Outstanding126,564,476
10 Day Avg. Volume378,207
30 Day Avg. Volume394,629
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)1.57
Price to Sales (P/S)0.00
P/FCF Ratio-4.74
Enterprise Value/Market Cap1.04
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-64.00
Enterprise Value/Ebitda-7.88
Forecast
1Y Price Target
$4.00Price Target Upside27.80% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.61
Revenue Forecast (FY)$1.50M
Nautilus Biotechnolgy Business Overview & Revenue Model
Company Description
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end...
How the Company Makes Money
null...
Nautilus Biotechnolgy Earnings Call Summary
Earnings Call Date:Feb 26, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 05, 2026
Earnings Call Sentiment Positive
The call emphasized meaningful technical progress, strong external validation, the successful public debut of the Voyager instrument, the early launch of an Early Access Program (Tau assay) and disciplined expense reductions that improved cash burn and extended runway through 2027. Offsetting these positives are limited near-term revenue (modest 2026 services revenue targeted at ~$0.5M), no current sales organization, and a planned increase in 2026 operating expenses and cash burn as the company invests to advance commercialization. On balance, the developments point to a company transitioning from development to early customer engagement with tangible validation and a clear commercialization timeline, though revenue and commercial execution risks remain in the near term.Positive Updates
Voyager Instrument Debut and Positive Community Reception
Public unveiling of the Nautilus Voyager instrument at US HUPO with highly positive feedback from researchers; provided the proteomics community its first tangible view of the system and reinforced interest from prospective customers.
Negative Updates
Limited Near-Term Revenue and Delayed Commercial Ramp
Early Access engagements are not expected to drive material revenue in 2026; management projects modest services revenue (targeting ~ $0.5M for 2026) with primary instrument and consumables revenue expected to ramp in 2027 when instrument placements begin.
Read all updates
Q4-2025 Updates
Positive
Negative
Voyager Instrument Debut and Positive Community Reception
Public unveiling of the Nautilus Voyager instrument at US HUPO with highly positive feedback from researchers; provided the proteomics community its first tangible view of the system and reinforced interest from prospective customers.
Read all positive updates
Company Guidance
Nautilus provided clear financial and commercial guidance: it finished the quarter with $156.1M in cash, reported 2025 cash burn of $50.2M (down from $57.8M in 2024), FY2025 operating expenses of $66.8M (‑18% YoY) with R&D $41.1M (‑19%) and G&A $25.7M (‑17%), and Q4 operating expenses of $15.4M (‑23% YoY); for 2026 the company expects total operating expenses to rise ~15–20% and full‑year cash burn of $65–70M, which it says supports a cash runway through 2027; revenue guidance calls for modest services revenue later in 2026 (management targets roughly $0.5M for 2026) plus recognition of Michael J. Fox Foundation-funded work (~$1.2M to Nautilus over ~18 months, with a portion in 2026 and the remainder in 2027), while commercial milestones include Early Access (Tau) sample processing by end of Q1 2026, preorders late 2026, instrument installations beginning early 2027, GA at launch of Voyager plus Tau and a second proteoform assay, and broadscale GA in H1 2027.Nautilus Biotechnolgy Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
52
Neutral
Cash Flow
26
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -6.46M | -6.35M | -5.71M | -3.42M | -2.84M |
| EBITDA | -52.54M | -64.43M | -74.30M | -54.51M | -47.47M |
| Net Income | -59.00M | -70.78M | -63.67M | -57.92M | -50.31M |
Balance Sheet | |||||
| Total Assets | 191.11M | 242.74M | 305.56M | 350.05M | 398.45M |
| Cash, Cash Equivalents and Short-Term Investments | 103.41M | 129.89M | 173.42M | 184.47M | 345.73M |
| Total Debt | 30.02M | 30.48M | 34.63M | 30.33M | 30.03M |
| Total Liabilities | 34.14M | 34.01M | 40.21M | 35.13M | 34.87M |
| Stockholders Equity | 156.97M | 208.73M | 265.35M | 314.92M | 363.58M |
Cash Flow | |||||
| Free Cash Flow | -51.97M | -61.27M | -54.15M | -48.13M | -41.51M |
| Operating Cash Flow | -50.70M | -59.15M | -51.71M | -45.81M | -39.24M |
| Investing Cash Flow | 35.22M | 66.25M | -43.73M | -25.74M | -138.96M |
| Financing Cash Flow | 214.00K | 1.14M | 368.00K | 562.00K | 327.45M |
Nautilus Biotechnolgy Technical Analysis
Positive
3.13
Price Trends
2.67
Positive
2.34
Positive
1.61
Positive
Market Momentum
0.21
Positive
51.38
Neutral
10.96
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NAUT, the sentiment is Positive. The current price of 3.13 is below the 20-day moving average (MA) of 3.15, above the 50-day MA of 2.67, and above the 200-day MA of 1.61, indicating a neutral trend. The MACD of 0.21 indicates Positive momentum. The RSI at 51.38 is Neutral, neither overbought nor oversold. The STOCH value of 10.96 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NAUT.
Nautilus Biotechnolgy Risk Analysis
Nautilus Biotechnolgy disclosed 68 risk factors in its most recent earnings report. Nautilus Biotechnolgy reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Nautilus Biotechnolgy Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $396.15M | -4.17 | -33.64% | ― | ― | 11.15% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $95.35M | -1.64 | -26.04% | ― | 13.77% | -4.76% | |
47 Neutral | $132.91M | -2.97 | -73.11% | ― | ― | 63.31% | |
45 Neutral | $21.80M | -0.37 | ― | ― | -33.00% | 54.91% | |
45 Neutral | $186.31M | -1.27 | -97.41% | ― | ― | -60.99% |
* Healthcare Sector Average
NAUT
Nautilus Biotechnolgy
3.13
2.32
286.42%
VTGN
VistaGen Therapeutics
0.55
-1.51
-73.30%
KLRS
Kalaris Therapeutics
6.34
-1.37
-17.77%
SEER
Seer
1.69
-0.27
-13.78%
ABOS
Acumen Pharmaceuticals
2.58
1.52
143.40%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.